C-B5LQJunevity
siRNA, gene network reset, machine learning
reprogrammingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-B5LQ
C-B5LQC-B5LQsiRNA, gene network reset, machine learning
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Junevity states that diseases shortening human lifespan are associated with cellular damage at the transcriptional level, and that restoring the expression of transcription factors to healthy levels can return aged human cells back to health. The company presents its RESET Platform as using large-scale human data, AI, transcriptomics, and siRNA to develop therapeutics that reverse disease and improve longevity across conditions such as obesity, type 2 diabetes, and frailty.
SourceJunevity states that diseases of aging can be rewound with novel transcription factor medicines. Its position is that targeting a single downstream gene cannot reverse complex age-related disease, whereas transcription factors act as upstream 'manager' genes that can return aged, diseased cells to health. The company also states that its REWIND discovery platform identifies novel targets for age-related diseases by combining genomics, machine learning, CRISPR, and aging biology, and that these therapies can help drive a rejuvenation-led healthcare system.
Source